• 1
    Kessel JB, Simson GM. Tricyclic and tetracyclic drugs. In: KaplanHI, SadockBJ (eds). Comprehensive Textbook of Psychiatry. Williams & Wilkins, Baltimore, 1995; 20962112.
  • 2
    Potter WZ, Zavadil III AP, Kopin IJ, Goodwin FK. Single dose kinetics predicts steady-state concentrations on imipramine and desimipramine. Arch. Gen. Psychiatry 1980; 37: 314320.
  • 3
    Timotijevic I, Zdravkovic M, Pokrajac M, Miljkovic B, Stojkovic M, Marinkovic O. Correlation of mono and combined amitriptyline/lithium therapy with therapeutic and side effects. Rom. J. Physiol. 1994; 31: 103111.
  • 4
    Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: HardmanJG, LimbirdLE, MolinoffPB, RuddonRW, GilmanAG (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 1996; 17071792.
  • 5
    Jankovic SM, Timotijevic I, Mihajlovic GS, Djukic Dejanovic S. Comparison of two approaches to amitriptyline dose individualization. Eur. J. Drug Metab. Pharmacokinet. 1999; 24: 163168.
  • 6
    Timotijevic I, Paunovic VR. [The Instruments of Clinical Assessment in Psychiatry.] Scientific Book, Belgrade, 1992 (in Serbian).
  • 7
    Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J. Clin. Psychopharmacol. 1994; 14: 230240.
  • 8
    Corona GL, Cucchi ML, Frattini P et al. Aspects of amitriptyline and nortriptyline plasma level monitoring in depression. Psychopharmacology (Berl.) 1990; 100: 334338.
  • 9
    Furlanut M, Benetelllo P, Spina E. Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin. Pharmacokinet. 1993; 24: 301318.
  • 10
    Schulz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. Clin. Pharmacokinet. 1985; 10: 257268.
  • 11
    Jankovic SM. Individualization of antibiotic dose regime in surgical patients. Specialist's thesis. Medical Faculty, University of Belgrade, 1996.
  • 12
    Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br. J. Psychiatry 2001; 178: 129144.
  • 13
    Ellis PM, Smith DA. Treating depression: the beyondblue guidelines for treating depression in primary care. ‘Not so much what you do but that you keep doing it’. Med. J. Aust. 2002; 176 (Suppl.): S77S83.
  • 14
    Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants:  efficacy,  safety,  and  cost  effectiveness. J. Clin. Psychiatry 1991; 52 (Suppl.): 2333.
  • 15
    Skomedal T, Osnes JB, Johannessen SI, Lund PK, Aass H. Therapeutic drug monitoring with the help of serum concentration measurements. How are the analytical results distributed in a population? Tidsskr. Nor. Laegeforen 1993; 113: 22422246.
  • 16
    Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin. Pharmacokinet. 2002; 41: 853876.
  • 17
    Pidrman V, Krpalek P. Side effects of amitriptyline in relation to its plasma levels. Cesk. Psychiatrie 1998; 88: 106112.
  • 18
    Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur. Neuropsychopharmacol. 1997; 7: 207212.